Literature DB >> 6548796

The natural history of initially untreated low-grade non-Hodgkin's lymphomas.

S J Horning, S A Rosenberg.   

Abstract

To learn more about the natural history of low-grade non-Hodgkin's lymphoma, we have studied 83 patients in whom the advanced disease was initially managed without therapy. Actuarial survival was 82 per cent at 5 years and 73 per cent at 10 years. The median time until therapy was required was three years. Spontaneous regressions occurred in 19 untreated patients (23 per cent), including 30 per cent of patients with nodular, poorly differentiated lymphocytic lymphoma. Histologic transformation to an intermediate-grade or high-grade lymphoma occurred both before and after primary therapy. The actuarial risk of transformation among the initially untreated patients was similar to that in a group of patients treated at this institution immediately after diagnosis. Neither the time to histologic transformation nor the incidence of transformation was influenced by when therapy was started.

Entities:  

Mesh:

Year:  1984        PMID: 6548796     DOI: 10.1056/NEJM198412063112303

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  123 in total

Review 1.  Management of non-Hodgkin's lymphomas.

Authors:  P J Mounter; A L Lennard
Journal:  Postgrad Med J       Date:  1999-01       Impact factor: 2.401

2.  Primary gastrointestinal follicular center lymphoma resembling multiple lymphomatous polyposis.

Authors:  Y Sakata; R Iwakiri; H Sakata; J Fujisaki; M Mizuguchi; N Fukushima; K Fujimoto
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

3.  Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes.

Authors:  Izidore S Lossos; Ash A Alizadeh; Maximilian Diehn; Roger Warnke; Yvonne Thorstenson; Peter J Oefner; Patrick O Brown; David Botstein; Ronald Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-19       Impact factor: 11.205

4.  Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.

Authors:  Kojo S J Elenitoba-Johnson; Stephen D Jenson; Robert T Abbott; Robert A Palais; Sandra D Bohling; Zhaosheng Lin; Sheryl Tripp; Paul J Shami; Lai Y Wang; Robert W Coupland; Rena Buckstein; Bayardo Perez-Ordonez; Sherrie L Perkins; Ian D Dube; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-19       Impact factor: 11.205

5.  Multi-locus HLA class I and II allele and haplotype associations with follicular lymphoma.

Authors:  C F Skibola; N K Akers; L Conde; M Ladner; S K Hawbecker; F Cohen; F Ribas; H A Erlich; D Goodridge; E A Trachtenberg; M T Smith; P M Bracci
Journal:  Tissue Antigens       Date:  2012-02-02

6.  Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.

Authors:  Efrat Dotan; Charu Aggarwal; Mitchell R Smith
Journal:  P T       Date:  2010-03

7.  A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.

Authors:  Amanda P Liggins; Seah H Lim; Elizabeth J Soilleux; Karen Pulford; Alison H Banham
Journal:  Cancer Immun       Date:  2010-08-23

Review 8.  Lymphocyte predominant Hodgkin's disease.

Authors:  Bradley C Ekstrand; Sandra J Horning
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

9.  Primary follicular lymphoma in a male breast: a case report.

Authors:  Seung Pil Jung; Kang Min Han; Seok Jin Kim; Seok Jin Nam; Jeoung Won Bae; Jeong Eon Lee
Journal:  Cancer Res Treat       Date:  2014-01-15       Impact factor: 4.679

Review 10.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.